ArticleInternational journal of clinical and experimental pathology2015
Expression of miR-203 is decreased and associated with the prognosis of melanoma patients.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.Molecular diagnosis & therapy · 2018Pooled it
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.Diagnostics (Basel, Switzerland) · 2025Review
- Omics in Cutaneous Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.Journal of cellular and molecular medicine · 2025Article
- MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection-Narrative Review.International journal of molecular sciences · 2023Review
- RETRACTED: Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.PloS one · 2023Article
- Selective targeting of α7 nicotinic acetylcholine receptor by synthetic peptide mimicking loop I of human SLURP-1 provides efficient and prolonged therapy of epidermoid carcinomaFrontiers in cell and developmental biology · 2023Article
- Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.International journal of molecular sciences · 2022Review
- Review
- A Comparative View on Molecular Alterations and Potential Therapeutic Strategies for Canine Oral Melanoma.Veterinary sciences · 2021Review
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- Identification of ATP2C1 mutations in the patients of Hailey-Hailey disease.BMC medical genetics · 2020Article
- Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy.Skin pharmacology and physiology · 2020Review
- miRNAs in the Diagnosis and Prognosis of Skin Cancer.Frontiers in cell and developmental biology · 2020Review
- Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.Cancer medicine · 2019Observational
- Advances in the Application and Impact of MicroRNAs as Therapies for Skin Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017Review
- MicroRNA-203 predicts human survival after resection of colorectal liver metastasis.Oncotarget · 2017Article
- RAB22A overexpression promotes the tumor growth of melanoma.Oncotarget · 2016Article
- Pivotal MicroRNAs in Melanoma: A Mini-Review.Molecular diagnosis & therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs or miRs) are a class of small, non-coding RNAs that can regulate the gene expression in various diseases. MicroRNA-203 (miRNA-203 or miR-203) has previously shown significant alteration in a number of cancers. However, the clinical value of miR-203 in melanoma is rarely reported. The present study aimed to clarify the expression pattern and prognostic role of miR-203 in melanoma patients. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression level of miR-203 in 148 cases of melanoma tissues and adjacent non-cancerous tissues. Results showed that miR-203 expression was significantly decreased in melanoma tissues compared with that in adjacent non-cancerous tissues (P<0.05). Additionally, chi-square was performed to analyze the relationship between miR-203 and clinicopathological features and the down-regulation of miR-203 was significantly associated with tumor thickness and tumor stage (P<0.05). Moreover, Kaplan-Meier analysis showed that low miR-203 expression was associated with short overall survival time of patients. Multivariate analysis indicated that miR-203 could be an independent prognostic marker (P=0.003, HR=2.851, 95% CI=1.439-5.650) in melanoma This study for the first time provided evidence that miR-203 could be an independent potential prognostic marker for patients with melanoma, and might even become a new therapeutic target for the treatment of melanoma.
Indexed as
Identifiers
26722525PMC4680470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.